Trial Profile
Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms RISE-M
- 17 Mar 2021 Status changed from active, no longer recruiting to discontinued.(the study was stoppe due to Lack of patient accruals).
- 31 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.